NCT06282991 2026-03-10
A Study to Learn About Lorlatinib in Patients With Non-Small Cell Lung Cancer Which Could Not Be Controlled
Pfizer
Completed
Clinical Trials
10 trialsNCT06678555 2026-02-05
A Study to Learn About Lorlatinib in Patients With Non-Small Cell Lung Cancer (NSCLC) Which Has Spread Out.
Pfizer
Active not recruiting
NCT05834348 2025-03-30
DELINOR
Pfizer
Completed
NCT06876675 2025-03-14
LORLATINIB-related HYPERLIPIDEMIA in ALK+ Non-Small Cell Lung Cancer
Peking University Third Hospital
Enrolling by invitation
NCT06690541 2024-11-15
COMLORLA
Peking University Cancer Hospital & Institute
Not yet recruiting
NCT06532149 2024-08-09
EROS
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Recruiting
NCT03546894 2024-07-15
A Study to Determine Progression-free Survival (PFS) and Evaluate Participant Experience for Participants With Metastatic Anaplastic Lymphoma Kinase-positive (ALK+) Non-Small Cell Lung Cancer (NSCLC) Treated With Anaplastic Lymphoma Kinase (ALK) Inhibitors
Takeda
Completed
NCT06361589 2024-04-12
Real World Study of Lolatinib for Advanced ALK+ NSCLC Patients
Sichuan Cancer Hospital and Research Institute
Recruiting
NCT04647110 2023-04-06
Real-world Therapy of ALK-positive NSCLC in Sweden: the Sequencing of ALK Tyrosine Kinase Inhibitor Drugs and Their Therapeutic Outcomes Based on Data From National Registers.
Pfizer
Completed
NCT05167500 2023-03-30
LORLAPULM
Fundación GECP
Completed